Apax Partners to acquire the operating subsidiaries of Invent Farma
![](/46/pdcnewsitem/04/16/96/invent%20farma.png)
Invent Farma develops, manufactures and markets generic drugs.
Funds advised by Apax Partners announced that an entity controlled by them has entered into a definitive agreement to acquire the operating subsidiaries of Invent Farma, a leading Spanish pharmaceutical company, from a consortium of investors led by Silfurberg, Framtakssjóður Íslands (Enterprise Investment Fund) and Horn II.
The transaction is expected to close in the next few months. Terms of the transaction were not disclosed.
Located in Barcelona, Invent Farma develops, manufactures and markets generic drugs. It owns and operates manufacturing plants in Spain and comprises three divisions:
• Inke, a manufacturer of APIs, which has a unique expertise in the respiratory area
• Lesvi, a highly flexible manufacturer of finished dosage forms, which has capabilities across multiple therapeutic areas
• Qualigen, which markets generic drugs in Spain and has a leading and rapidly growing franchise in the central nervous system field.
Steven Dyson, Partner and Co-Head of Healthcare at Apax Partners, said: “We have identified the European generics space as an attractive investment area. We are excited to build on Invent Farma’s success, particularly on their strength in respiratory APIs and their outstanding CNS franchise. We will look to support the organic growth of Invent Farma as well as further consolidate the European generics market, as evidenced by our recent announcement of a transaction with Germany’s neuraxpharm.”
Friðrik Steinn Kristjánsson, chairman of Invent Farma and owner of Silfurberg said: “We are very proud of Invent Farma's achievements in Spain, Europe and globally across all of its three business units, namely Inke, Lesvi, and Qualigen. On behalf of the Shareholders, I would like to thank the management and employees of Invent for their dedication, commitment and expertise, which led to the Company performing very well under our ownership with significant revenue and profit growth."
Commenting on the transaction, Ervin Veszprémi, CEO of Invent Farma: "We want to thank our previous shareholders for their continued support offered during all these years. We are delighted to be partnering with Apax. With their experience in both healthcare and 'buy-and-build' strategies, they will provide invaluable expertise and investment as we enter this next phase of growth."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance